The release of Open AI’s ChatGPT sparked an era of artificial intelligence (AI) revolutions from education to engineering. More recently, Harvard Medical School has brought that development to medicine as well.
Researchers at the university have studied CHIEF (Clinical Histopathology Imaging Evaluation Foundation), an AI medical tool that can accurately detect multiple forms of cancer. It’s considered revolutionary compared to current AI systems because it can identify numerous cancer types as opposed to performing one specific task. In fact, CHIEF surpasses other leading AI systems by over 36% in key areas such as detecting cancer cells, predicting patient outcomes, identifying tumor origins, and recognizing specific genes and DNA patterns that influence how patients respond to treatments.
Behind the success of CHIEF is an intense training regime that analyzes digital slides of tumor conditions. The regime detects cancer cells and can predict the tumor’s molecular profile based on specified image features. CHIEF was initially trained on over 15 million unlabeled images before being trained further to look at specific sections of the body in order to interpret the images in a border context. It performs similarly to a ChatGPT chatbot with its versatility and ability to complete many tasks. This training has translated into success, with CHIEF achieving nearly 94% accuracy in cancer detection. This is considered revolutionary, as CHIEF helps doctors predict patient survival across different cancer types and can pinpoint specific features of the tumor that change how a patient reacts to surgery, chemotherapy, radiation, and immunotherapy.
CHIEF can efficiently identify cellular patterns in the genetic makeup of different tumors. This process is integral since understanding the genetic makeup of a tumor gives doctors the evidence needed to understand its future behavior and potential treatments options. If CHIEF was implemented, the time and money it would save could be critical to the thousands of cancer patients who suffer from long diagnoses and expensive medical bills. It would also help to bridge the gap between well-resourced regions that can afford detailed genomic profiling and those that cannot.
Ultimately , CHIEF proved that AI is coming to healthcare with the potential to change cancer evaluation forever. However, before it can be released to the public, the researchers are refining CHIEF by conducting additional training in molecular data, rare diseases, cancer treatments, and pre-malignant tissues. Despite its pending release, the foundation CHIEF has created has opened new horizons to the world of AI with the possibility of transforming disease detection forever.
For more information click here
Leave a Reply